

## Zelnorm-Recall.com Launched by Hissey Kientz, LLP

Zelnorm-Recall.com contains medical and legal information about the irritable bowel syndrome drug Zelnorm and the latest news concerning the potential Zelnorm recall.

(<u>PRWEB</u>) May 24, 2007 -- The law firm of Hissey Kientz, LLP has announced the launch of its new website, Zelnorm-Recall.com. This new site will provide patients with information about the potential health risks of Zelnorm, as well as medical and legal information concerning the recent <u>recall of Zelnorm</u> in the United States.

Zelnorm was designed to treat the symptoms of constipation associated with irritable bowel syndrome (IBS). Initially, the drug was rejected by the Food and Drug Administration due to a link between Zelnorm and abdominal problems, and its limited effectiveness at treating IBS. Zelnorm was eventually approved in July 2002, despite studies indicating an increased risk of ovarian cysts among Zelnorm patients.

After a routine safety review of Zelnorm in February 2007, the FDA was informed of clinical trial data concerning the drug which indicated that Zelnorm users were at an increased risk of cardiovascular side effects compared to patients treated with a placebo. Because of this risk, Zelnorm patients were about eight times more likely to suffer heart attack, stroke or other cardiovascular side effects.

Based on this information, Novartis Pharmaceuticals, the manufacturer of Zelnorm, withdrew the drug in the United States at the FDA's request. As a result, Zelnorm will no longer be sold or marketed in the United States. The FDA says that Novartis is planning to issue a full Zelnorm recall, although no date has been announced.

In addition to providing information about the withdrawal, Zelnorm-Recall.com contains information about the <u>Zelnorm side effects</u> associated with the drug and legal advice for patients who were injured by taking are considering filing a <u>Zelnorm lawsuit</u>. The website will also be regularly updated to keep patients informed about the latest news concerning the anticipated Zelnorm recall and potential claims or lawsuits.

## About Hissey Kientz, LLP

Hissey Kientz, LLP is handling or investigating cases involving people affected by mesothelioma, ReNu with MoistureLoc, Fosamax, Tequin, Remicade, heart devices, the Kugel hernia patch, hormone replacement therapy and other defective drugs and devices. To learn more about the firm and other drug cases, visit Hissey Kientz, LLP (<u>www.hkllp.com</u>) or call (866) 275-4454.

```
###
```



Contact Information Todd Greenbaum Hissey Kientz, LLP <u>http://www.zelnorm-recall.com</u> 866 275-4454

## **Online Web 2.0 Version**

You can read the online version of this press release here.

PRWebPodcast Available Listen to Podcast MP3 Listen to Podcast iTunes Listen to Podcast OGG